Literature DB >> 16371840

Caspase-3, caspase-8, and nuclear factor-kappaB expression in human cholesteatoma.

Masumichi Miyao1, Hideo Shinoda, Sugata Takahashi.   

Abstract

BACKGROUND: Cholesteatoma is characterized by the accumulation of keratinizing epithelium resulting from the proliferation and differentiation of epithelium. Researchers are presently unraveling the role that apoptosis plays in the disease seen in cholesteatoma epithelium. Caspases play a key role in apoptosis. Caspase-8, which is activated by the induction of tumor necrosis factor-alpha, leads to activation of caspase-3, which activates apoptotic nucleases. Nuclear factor-kappaB is a transcription factor known to inhibit apoptosis induced by tumor necrosis factor-alpha. HYPOTHESIS: In this study, we hypothesized that expression of caspase-3, caspase-8, and nuclear factor-kappaB is uniquely connected to the proliferation, differentiation, and programmed cell death of keratinocytes during the growth and development of cholesteatoma.
METHODS: We obtained 41 cholesteatoma specimens for this study. The presence of these proteins in cholesteatoma was examined using immunohistochemistry and a colorimetric assay system. We also examined the patterns of apoptosis by using terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining.
RESULTS: Using the immunoperoxidase staining method, caspase-3 was found to be densely localized in the spinous and granular layers of cholesteatoma epithelium; caspase-8 was also found in the granular layer. Nuclear factor-kappaB was localized densely in the perinuclear region of the epithelium. The results obtained with immunoperoxidase staining agreed with those obtained with terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining. In addition, the colorimetric assay method was used to measure the activity of caspase-3.
CONCLUSION: These findings suggest that caspase-3 and caspase-8 play important roles in programmed cell death, which results in the accumulation of keratin debris during the growth of cholesteatoma. Nuclear factor-kappaB was found in cholesteatoma epithelium, but the transcription factor appeared to be inactivated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16371840     DOI: 10.1097/01.mao.0000180482.34545.b8

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  5 in total

1.  LRRC4, a putative tumor suppressor gene, requires a functional leucine-rich repeat cassette domain to inhibit proliferation of glioma cells in vitro by modulating the extracellular signal-regulated kinase/protein kinase B/nuclear factor-kappaB pathway.

Authors:  Minghua Wu; Chen Huang; Kai Gan; He Huang; Qiong Chen; Jue Ouyang; Yunlian Tang; Xiaoling Li; Yixin Yang; Houde Zhou; Yanhong Zhou; Zhaoyang Zeng; Lan Xiao; Dan Li; Ke Tang; Shourong Shen; Guiyuan Li
Journal:  Mol Biol Cell       Date:  2006-05-24       Impact factor: 4.138

2.  Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.

Authors:  Jae Yong Byun; Tae Young Yune; Jee Youn Lee; Seung Geun Yeo; Moon Suh Park
Journal:  Mediators Inflamm       Date:  2010-04-21       Impact factor: 4.711

3.  Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21.

Authors:  David R Friedland; Rebecca Eernisse; Christy Erbe; Nidhi Gupta; Joseph A Cioffi
Journal:  Otol Neurotol       Date:  2009-10       Impact factor: 2.311

4.  Chlorella vulgaris triggers apoptosis in hepatocarcinogenesis-induced rats.

Authors:  Emey Suhana Mohd Azamai; Suhaniza Sulaiman; Shafina Hanim Mohd Habib; Mee Lee Looi; Srijit Das; Nor Aini Abdul Hamid; Wan Zurinah Wan Ngah; Yasmin Anum Mohd Yusof
Journal:  J Zhejiang Univ Sci B       Date:  2009-01       Impact factor: 3.066

5.  Immunomodulation as a Protective Strategy in Chronic Otitis Media.

Authors:  Anke Leichtle; Arwa Kurabi; David Leffers; Markus Därr; Clara Sophia Draf; Allen Frederic Ryan; Karl-Ludwig Bruchhage
Journal:  Front Cell Infect Microbiol       Date:  2022-03-30       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.